
    
      -  Participants will receive ofatumumab once a week for 8 weeks by intravenous infusion
           (Days 1, 8, 15, 22, 29, 36, 43, and 50).

        -  Participants will be seen weekly during the 8 week treatment period and will have the
           following tests and procedures performed: Blood tests, performance status and physical
           examination.
    
  